Managed Healthcare Executive February 24, 2024
At the moment, Simlandi (adalimumab-ryvk) has the high-concentration, citrate-free, interchangeable Humira (adalimumab) market to itself.
The FDA has approved Simlandi (adalimumab-ryvk), which joins Pfizer’s Abrilada (adalimumab-afzb) and Boehringer Ingelheim’s Cyltezo (adalimumab-adbm) as interchangeable with AbbVie’s Humira’s (adalimumab), the reference brand-name product that has set all kinds of sales records, for some uses.
Interchangeability means the biosimilar can be substituted for the reference product or another biosimilar at the pharmacy level, although state-level pharmacy regulations can complicate matters. Interchangeability is widely seen as important for gaining market share in the increasingly crowded market for Humira biosimilars and for pharmacy benefit managers (PBMs) steering prescriptions to their preferred products.
A total of nine Humira biosimilars are on the market in the U.S.,...
Today's Sponsors
Today's Sponsor